March 12, 2009

To whom it may concern:

5-2-1 Daizawa, Setagaya Ward, Tokyo
Toho Pharmaceutical Co., Ltd.
(Tokyo Stock Exchange Securities Code: 8129)
Norio Hamada, President and CEO
contact:
Mamoru Ogino
Executive Corporate Officer,
Joint General Manager of Administration Division
(TEL: 03-4330-3735)

Notice of Purchase of Company Stock from a Subsidiary
(Acquisition of Company Stock Pursuant to the Provisions of Article 163 of the Corporations Law)

Toho Pharmaceutical Co., Ltd. hereby announces that the company’s Board of Directors, at its meeting held today (March 12, 2009), resolved the company’s acquisition of its stock held by one of its subsidiaries, pursuant to the provisions of Article 156 of the Corporations Law, as applied mutatis mutandis under Article 163 of the said Law, as described below.

1. Name of the Subsidiary which Holds Company Stock
Sue Pharmaceutical Co., Ltd.

2. Acquisition Details
   (1) Type of stock to be acquired: Common stock of this company
   (2) Total number of shares to be acquired: 16,239
   (3) Total cost of stock to be acquired: 15,946,698 yen
      (The acquisition cost shall be 982 yen per share, which is the closing share price of the company’s common stock at the first section of the Tokyo Stock Exchange on March 11, 2009.)
   (4) Scheduled date for the stock acquisition: March 18, 2009

(For Reference)
Company Stock Held by the Company in Treasury as of March 11, 2009
(1) Number of shares issued and outstanding (excluding common stock for treasury): 59,619,048
(2) Number of shares held in treasury: 1,147,574